Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of “Buy” by Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have received a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $17.29.

Several analysts recently commented on the company. BMO Capital Markets raised their price objective on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research report on Friday, November 22nd. Jefferies Financial Group increased their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th.

Replimune Group Stock Performance

Shares of REPL stock opened at $12.62 on Wednesday. The stock has a market cap of $863.42 million, a PE ratio of -4.14 and a beta of 1.28. The stock has a 50-day moving average of $12.44 and a 200-day moving average of $11.03. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. Replimune Group has a one year low of $4.92 and a one year high of $17.00.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, sell-side analysts expect that Replimune Group will post -2.91 earnings per share for the current year.

Insider Transactions at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC lifted its position in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares during the last quarter. Braidwell LP raised its stake in Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after acquiring an additional 2,057,460 shares during the period. State Street Corp lifted its holdings in Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares during the last quarter. Baker BROS. Advisors LP increased its holdings in shares of Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after purchasing an additional 1,000,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC raised its position in shares of Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after purchasing an additional 238,747 shares during the period. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.